{"name": "AcelRx Pharmaceuticals",
 "permalink": "acelrx-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/acelrx-pharmaceuticals",
 "homepage_url": "http://www.acelrx.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@acelrx.com",
 "phone_number": "650-216-3500",
 "description": "",
 "created_at": "Fri Oct 08 04:13:41 UTC 2010",
 "updated_at": "Sat Jul 02 02:52:49 UTC 2011",
 "overview": "\u003Cp\u003EAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute post-operative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is based in Redwood City, California.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       45],
      "assets/images/resized/0010/4671/104671v1-max-150x150.png"],
     [[170,
       51],
      "assets/images/resized/0010/4671/104671v1-max-250x250.png"],
     [[170,
       51],
      "assets/images/resized/0010/4671/104671v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Richard",
      "last_name": "King",
      "permalink": "richard-king-2",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "James",
      "last_name": "Welch",
      "permalink": "james-welch-2",
      "image": null}},
   {"is_past": true,
    "title": "Board Member",
    "person":
     {"first_name": "Howard",
      "last_name": "B. Rosen",
      "permalink": "howard-b-rosen",
      "image":
       {"available_sizes":
         [[[127,
            150],
           "assets/images/resized/0025/7882/257882v1-max-150x150.jpg"],
          [[150,
            176],
           "assets/images/resized/0025/7882/257882v1-max-250x250.jpg"],
          [[150,
            176],
           "assets/images/resized/0025/7882/257882v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "575 Chesapeake Drive",
    "address2": "",
    "zip_code": "94063",
    "city": "Redwood City",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "AcelRx Pharmaceuticals aimed high but fell short. The Redwood City, CA-based devloper had hoped to raise $86 million in an initial offering of 8 million shares at $12 to $14 per share. But the company managed the garner just $5 per share for a total $40 m",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 11,
    "source_url": "http://www.fiercebiotech.com/story/acelrx-falls-short-40m-ipo/2011-02-11?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "AcelRx falls short in $40M IPO",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AcelRx Pharmaceuticals",
      "permalink": "acelrx-pharmaceuticals"}},
   {"description": "AcelRx gets $20M loan for Phase III work",
    "stoned_year": 2011,
    "stoned_month": 7,
    "stoned_day": 1,
    "source_url": "http://www.fiercebiotech.com/story/acelrx-gets-20m-loan-phase-iii-work/2011-07-01?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "AcelRx gets $20M loan for Phase III work",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "AcelRx Pharmaceuticals",
      "permalink": "acelrx-pharmaceuticals"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}